Rui Han

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 11

Top Topics

Prognostic Factors

Ejection Fraction

Dendritic Cells

Top Venues

International journal of nanomedicine

Cancer cell international

This page only lists publications with an associated author ORCID identifier.

Publications

Rui Han, Xiwu Rao, Huiling Zhou, Changquan Ling
Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy. International journal of nanomedicine 19 (2024)
Rui Han, Xiwu Rao, Huiling Zhou, Changquan Ling
Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy. International journal of nanomedicine 19 (2024)
Huiling Zhou, Wentao Jia, Changquan Ling, Rui Han
MicroRNAs with Multiple Targets of Immune Checkpoints, as a Potential Sensitizer for Immune Checkpoint Inhibitors in Breast Cancer Treatment. Cancers 15 (3) (2023)
Yuqian Wang, Changquan Ling, Changquan Ling, Ping Zhang, Rui Han
Potential of Dietary HDAC2i in Breast Cancer Patients Receiving PD-1/PD-L1 Inhibitors. Nutrients 15 (18) (2023)
Rui Han, Changquan Ling, Yuqian Wang, Lingeng Lu
Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition. Cancer cell international 23 (1) (2023)
Rui Han, Yuqian Wang, Changquan Ling
Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment. Pharmaceutics 16 (1) (2023)
Rui Han, Yuqian Wang, Changquan Ling
Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment. Pharmaceutics 16 (1) (2023)
Huiling Zhou, Wentao Jia, Changquan Ling, Rui Han
MicroRNAs with Multiple Targets of Immune Checkpoints, as a Potential Sensitizer for Immune Checkpoint Inhibitors in Breast Cancer Treatment. Cancers 15 (3) (2023)
Rui Han, Yuqian Wang, Changquan Ling
Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment. Pharmaceutics 16 (1) (2023)
Rui Han, Hongxing Yang, Ya Li, Changquan Ling, Lingeng Lu
Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer. Medical oncology (Northwood, London, England) 39 (12) (2022)
Rui Han, Hongxing Yang, Changquan Ling, Lingeng Lu
Tiliroside suppresses triple-negative breast cancer as a multifunctional CAXII inhibitor. Cancer cell international 22 (1) (2022)